Unibest
← Back to patent-cliff list

Fimepinostat

Tier C — Watch / trade

Fimepinostat

Curis Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:HDAC, Class I PI3K

Indications (approved):Cushing's syndrome, Glioma, Glioblastoma, Diffuse intrinsic pontine glioma, 髓母细胞瘤, 星形细胞瘤, Lymphoma, 脑癌

Regional status

US
Phase II
2016-07-01
EU
Phase I
2019-08-07
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 14 · Total yield 9.2 g (Fimepinostat)
FIMEP-00122288-78-4FIMEP-00216233-51-5FIMEP-003—FIMEP-004—FIMEP-005885618-31-5FIMEP-006955979-15-4FIMEP-00789793-12-4FIMEP-0081235450-25-5FIMEP-009163105-89-3FIMEP-0101339928-30-1FIMEP-011763-69-9FIMEP-0121086272-71-0FIMEP-01333458-27-4FIMEP-01491978-81-3FIMEP-0151628-89-3FIMEP-01613472-85-0Fimepinostat1339928-25-4API · Fimepinostat
CodeCAS No.Intermediate
FIMEP-00122288-78-4methyl 3-aminothiophene-2-carboxylate
FIMEP-00216233-51-5thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
FIMEP-003--
FIMEP-004--
FIMEP-005885618-31-52-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde
FIMEP-006955979-15-41-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-N-methylmethanamine
FIMEP-00789793-12-4Availableethyl 2-chloropyrimidine-5-carboxylate
FIMEP-0081235450-25-5ethyl 2-(((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate
FIMEP-009163105-89-3(6-methoxypyridin-3-yl)boronic acid
FIMEP-0101339928-30-1-
FIMEP-011763-69-9-
FIMEP-0121086272-71-0-
FIMEP-01333458-27-4-
FIMEP-01491978-81-3-
FIMEP-0151628-89-32-methoxypyridine
FIMEP-01613472-85-05-bromo-2-methoxypyridine
Fimepinostat1339928-25-4-

Frequently asked questions

What are the approved indications of Fimepinostat?

Approved indications include: Cushing's syndrome, Glioma, Glioblastoma, Diffuse intrinsic pontine glioma, 髓母细胞瘤, 星形细胞瘤, Lymphoma, 脑癌.

When does the Fimepinostat patent expire?

No public expiry year is available for Fimepinostat yet; this page updates once verified.

How many synthesis routes are recorded for Fimepinostat?

1 synthesis routes are recorded; the shortest is 14 steps with 9.2 g (Fimepinostat) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Fimepinostat intermediates?

1 intermediate CAS of Fimepinostat are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Fimepinostat intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-10